Evidence map›Paper›PMID 32511378›Full record

ArticlebioRxiv : the preprint server for biology2020

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.

Chunlong Ma, Michael D Sacco, Brett Hurst, Julia A Townsend, Yanmei Hu, Tommy Szeto, Xiujun Zhang, Bart Tarbet, Michael T Marty, Yu Chen and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 92 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Chunlong MaDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States.
Michael D SaccoDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Brett HurstInstitute for Antiviral Research, Utah State University, Logan, UT, 84322, USA.
Julia A TownsendDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, 85721, United States.
Yanmei HuDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States.
Tommy SzetoDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States.
Xiujun ZhangDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Bart TarbetInstitute for Antiviral Research, Utah State University, Logan, UT, 84322, USA.
Michael T MartyDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, 85721, United States.
Yu ChenDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Jun WangDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721, United States.
University of Arizona · USUniversity of South Florida · USUtah State University · US

Funding

Unravelling Membrane Protein-Lipid Interactions using Nanodiscs and Mass SpectrometryR35GM128624 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Michael T Marty · 2018 to 2026
$3.6M
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A ProteasesR01AI147325 · NIAID · UNIVERSITY OF ARIZONA · PI WANG, JUN · 2019 to 2022
$1.7M
NIAID NIH HHS N01 AI030048NIAID NIH HHS R01 AI147325NIGMS NIH HHS R35 GM128624
6 · The paper itself

Abstract

A novel coronavirus SARS-CoV-2, also called novel coronavirus 2019 (nCoV-19), started to circulate among humans around December 2019, and it is now widespread as a global pandemic. The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate of 6.96% as of May 4, 2020. There is no vaccine or antiviral available for SARS-CoV-2. In this study, we report our discovery of inhibitors targeting the SARS-CoV-2 main protease (M

Indexed as

3CL proteaseboceprevircalpain inhibitorsCOVID-19GC-376main proteaseSARS-CoV-2

Identifiers

PMID32511378
PMCPMC7263507
OpenAlexW3016316450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.